Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11680668,oral clearance (CL),"The population estimates and 90% confidence intervals (CI) for oral clearance (CL) and apparent volume of distribution of the plasma compartment (Vc) were 0.0176 l/h/kg (CI = 0.012-0.023) and 0.098 l/kg (CI = 0.088 - 0.109), respectively.",Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),[l] / [h·kg],0.0176,2486,DB06822,Tinzaparin
,11680668,apparent volume of distribution of the plasma compartment (Vc),"The population estimates and 90% confidence intervals (CI) for oral clearance (CL) and apparent volume of distribution of the plasma compartment (Vc) were 0.0176 l/h/kg (CI = 0.012-0.023) and 0.098 l/kg (CI = 0.088 - 0.109), respectively.",Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),[l] / [kg],0.098,2487,DB06822,Tinzaparin
,11680668,elimination half-life,The elimination half-life was 3.9 h (CI = 2.5-5.2).,Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),h,3.9,2488,DB06822,Tinzaparin
,21162606,bioavailability,The bioavailability of bemiparin was estimated at 96% and the apparent volume of distribution was 5.1 L.,Bemiparin: pharmacological profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),%,96,10989,DB06822,Tinzaparin
,21162606,apparent volume of distribution,The bioavailability of bemiparin was estimated at 96% and the apparent volume of distribution was 5.1 L.,Bemiparin: pharmacological profile. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),l,5.1,10990,DB06822,Tinzaparin
,21162606,half-life,Bemiparin has the longest half-life of all LMWH at 5.3 h compared with 0.5-1.0 h for unfractionated heparin.,Bemiparin: pharmacological profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),h,5.3,10991,DB06822,Tinzaparin
,21162606,half-life,Bemiparin has the longest half-life of all LMWH at 5.3 h compared with 0.5-1.0 h for unfractionated heparin.,Bemiparin: pharmacological profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),h,0.5-1.0,10992,DB06822,Tinzaparin
over,21162606,mean residence time,"Elimination is linear, with a mean residence time of over 7 h and total clearance of 0.9 L/h.",Bemiparin: pharmacological profile. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),h,7,10993,DB06822,Tinzaparin
,21162606,total clearance,"Elimination is linear, with a mean residence time of over 7 h and total clearance of 0.9 L/h.",Bemiparin: pharmacological profile. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),[l] / [h],0.9,10994,DB06822,Tinzaparin
below,15467910,peak anti-Xa,"Doses were adjusted when peak anti-Xa levels fell below 0.1 IU/ml and, in some cases, when levels at 10 and 18 hours post injection were undetectable (<0.05 IU/ml).",Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467910/),[iu] / [ml],0.1,26689,DB06822,Tinzaparin
below,15467910,peak,Our results showed that women receiving tinzaparin (50 IU/kg) frequently had peak (4 hour) anti-Xa levels below 0.1IU/ml and that 46% of these patients required dose adjustment.,Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467910/),[iu] / [ml],0.1,26690,DB06822,Tinzaparin
below,15467910,anti-Xa,Our results showed that women receiving tinzaparin (50 IU/kg) frequently had peak (4 hour) anti-Xa levels below 0.1IU/ml and that 46% of these patients required dose adjustment.,Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467910/),[iu] / [ml],0.1,26691,DB06822,Tinzaparin
,16697485,absolute bioavailabilities,Mean absolute bioavailabilities were 51% and 59% for the two tested doses.,Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16697485/),%,51,29171,DB06822,Tinzaparin
,16697485,absolute bioavailabilities,Mean absolute bioavailabilities were 51% and 59% for the two tested doses.,Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16697485/),%,59,29172,DB06822,Tinzaparin
,12200805,maximal anti-factor Xa (anti-Xa) activity,Mean maximal anti-factor Xa (anti-Xa) activity was 0.33 IU/mL 4.0 hours after SC administration and 1.33 IU/mL 0.25 hours after IV administration.,Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200805/),[iu] / [ml],0.33,41242,DB06822,Tinzaparin
,12200805,maximal anti-factor Xa (anti-Xa) activity,Mean maximal anti-factor Xa (anti-Xa) activity was 0.33 IU/mL 4.0 hours after SC administration and 1.33 IU/mL 0.25 hours after IV administration.,Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200805/),[iu] / [ml],1.33,41243,DB06822,Tinzaparin
,12200805,half-lives,"Anti-Xa half-lives were 3.89 and 2.31 hours, respectively.",Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200805/),h,3.89,41244,DB06822,Tinzaparin
,12200805,half-lives,"Anti-Xa half-lives were 3.89 and 2.31 hours, respectively.",Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200805/),h,2.31,41245,DB06822,Tinzaparin
,8212732,EC50,"The values of EC50 associated with the activation of a single 'receptor' and of a proposed additional 'receptor' were 3 and 13 micrograms/ml of heparin material, respectively.","Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212732/),[μg] / [ml],3,54436,DB06822,Tinzaparin
,8212732,EC50,"The values of EC50 associated with the activation of a single 'receptor' and of a proposed additional 'receptor' were 3 and 13 micrograms/ml of heparin material, respectively.","Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212732/),[μg] / [ml],13,54437,DB06822,Tinzaparin
,16411388,anti-Xa,"The objectives of the current study were to determine i) the once daily dose required to achieve anti-Xa levels of 0.5-1.0 IU/mL, ii) the pharmacokinetics and iii) preliminary safety data using tinzaparin.",Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411388/),,0.5-1.0,85994,DB06822,Tinzaparin
,15085465,peak drug level,Intravenous administration of the same dose resulted in a peak drug level of approximately 1.5 anti-Xa U/mL.,Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085465/),[u] / [ml],1.5,88757,DB06822,Tinzaparin
,15085465,elimination half-life,The elimination half-life was approximately 1 hour.,Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085465/),h,1,88758,DB06822,Tinzaparin
,15085465,peak drug concentrations,Intravenous administration of 175 U/kg resulted in peak drug concentrations of almost 5 anti-Xa U/mL.,Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085465/),[u] / [ml],5,88759,DB06822,Tinzaparin
,11234669,Anti-Xa,"Anti-Xa and anti-IIa activity levels on day 2 were 0.66 +/- 0.20 IU/mL (range: 0.26-1.04 IU/mL) and 0.33 +/- 0.10 IU/mL (range: 0.18-0.55 IU/mL), respectively.",[Monitoring of tinzaparin in a ten day treatment dose in elderly patients]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11234669/),[iu] / [ml],0.66,121390,DB06822,Tinzaparin
,11234669,anti-IIa activity,"Anti-Xa and anti-IIa activity levels on day 2 were 0.66 +/- 0.20 IU/mL (range: 0.26-1.04 IU/mL) and 0.33 +/- 0.10 IU/mL (range: 0.18-0.55 IU/mL), respectively.",[Monitoring of tinzaparin in a ten day treatment dose in elderly patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11234669/),[iu] / [ml],0.33,121391,DB06822,Tinzaparin
,11556655,clearance,The clearance of tinzaparin based on anti-Xa activity ranged from 1.14 to 2.04 L/hr.,Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556655/),[l] / [h],1.14 to 2.04,129369,DB06822,Tinzaparin
,11556655,volume of distribution,"The volume of distribution was 3.1-5.0 L, suggesting that the molecular entities responsible for anti-Xa and anti-IIa activities are confined to the intravascular space.",Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556655/),l,3.1-5.0,129370,DB06822,Tinzaparin
,11556655,half-life,The mean half-life of anti-Xa activity after s.c. injection ranged from 3.41 to 4.13 hours and was independent of the dose.,Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556655/),h,3.41 to 4.13,129371,DB06822,Tinzaparin
,11556655,absolute bioavailability,The mean absolute bioavailability of s.c. tinzaparin was 86.7%.,Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556655/),%,86.7,129372,DB06822,Tinzaparin
,21819539,accumulation ratio,No significant accumulation was detected: the mean accumulation ratio was 1.06 (90% CI 1.01-1.11).,No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819539/),,1.06,212099,DB06822,Tinzaparin
,15271419,Peak concentrations,"Peak concentrations in tissue and washes of stomach, duodenum, jejunum, ileum and colon were at 6-30, 15-30, 30 min, 2 and 4 h, respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),h,6-30,232480,DB06822,Tinzaparin
,15271419,Peak concentrations,"Peak concentrations in tissue and washes of stomach, duodenum, jejunum, ileum and colon were at 6-30, 15-30, 30 min, 2 and 4 h, respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),h,15-30,232481,DB06822,Tinzaparin
,15271419,Peak concentrations,"Peak concentrations in tissue and washes of stomach, duodenum, jejunum, ileum and colon were at 6-30, 15-30, 30 min, 2 and 4 h, respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),h,30,232482,DB06822,Tinzaparin
,15271419,Amounts,"Amounts found at peak times in combined tissue and washes accounted for 46% and 0.5% in stomach (15 min) and colon (4 h), respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),,15,232483,DB06822,Tinzaparin
,15271419,Amounts,"Amounts found at peak times in combined tissue and washes accounted for 46% and 0.5% in stomach (15 min) and colon (4 h), respectively.","Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15271419/),,4,232484,DB06822,Tinzaparin
,11248285,anti-Xa/anti-IIa ratios,"The anti-Xa/anti-IIa ratios of the drug substances were comparable at 1.5 and 1.7 for tinzaparin and the tinzaparin-like LMWH, respectively.",Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),,1.5,245557,DB06822,Tinzaparin
,11248285,anti-Xa/anti-IIa ratios,"The anti-Xa/anti-IIa ratios of the drug substances were comparable at 1.5 and 1.7 for tinzaparin and the tinzaparin-like LMWH, respectively.",Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),,1.7,245558,DB06822,Tinzaparin
,11248285,maximum plasma anti-Xa activity (A(max)),Mean maximum plasma anti-Xa activity (A(max)) was approximately 0.818 IU/ml at 4 h following tinzaparin injection.,Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),[iu] / [ml],0.818,245559,DB06822,Tinzaparin
,11248285,maximum plasma anti-IIa activity,Mean maximum plasma anti-IIa activity was 0.308 IU/ml at 5 h postdose.,Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),[iu] / [ml],0.308,245560,DB06822,Tinzaparin
,7997983,half-lives,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),min,15,251953,DB06822,Tinzaparin
,7997983,half-lives,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),min,90,251954,DB06822,Tinzaparin
,7997983,terminal elimination phase,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),min,15,251955,DB06822,Tinzaparin
,7997983,terminal elimination phase,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),min,90,251956,DB06822,Tinzaparin
,7997983,terminal elimination phase,"The decay in plasma could be described by a three-compartment model with half-lives of the two distributive phases and the terminal elimination phase of 15 min, 90 min, and 37 hrs, respectively.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),h,37,251957,DB06822,Tinzaparin
,7997983,accumulation ratios,"Drug-related radioactivity accumulated gradually with repeated dosing, reaching accumulation ratios between 5 and 9, when based on trough concentrations.",Pharmacokinetics of tinzaparin (Logiparin)--a low molecular weight heparin--after single and repeated intravenous administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997983/),,5 and 9,251958,DB06822,Tinzaparin
,11011804,MW,"The mean MW of these compounds ranges from 3,600 to 6,500 daltons.",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),daltons,"3,600 to 6,500",267803,DB06822,Tinzaparin
,11011804,retention time,"The mean retention time of aXa activity varies from 5.2 (dalteparin) to approximately 7 h (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),h,5.2,267804,DB06822,Tinzaparin
,11011804,retention time,"The mean retention time of aXa activity varies from 5.2 (dalteparin) to approximately 7 h (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),h,7,267805,DB06822,Tinzaparin
,11011804,Bioavailability,"Bioavailability of prophylactic doses of LMWHs ranges from 86% (dalteparin) to 98% (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),%,86,267806,DB06822,Tinzaparin
,11011804,Bioavailability,"Bioavailability of prophylactic doses of LMWHs ranges from 86% (dalteparin) to 98% (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),%,98,267807,DB06822,Tinzaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],16,267808,DB06822,Tinzaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],21,267809,DB06822,Tinzaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],33,267810,DB06822,Tinzaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],19,267811,DB06822,Tinzaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],22,267812,DB06822,Tinzaparin
